Clinical trial Recruiting at 1 site Phase2; Phase3 Interventional Ages 18 to 50 Men only

Effects of rifaximin on gut bacteria and emotional responses

Official title: A Randomized, Triple-blind, Placebo-controlled Study on the Effect of Rifaximin on Psychobiological Functions in Healthy Men

Run by Universitaire Ziekenhuizen KU Leuven · NCT05587036 · Data updated 2026-11-12

This study is testing if the antibiotic rifaximin can change gut bacteria and affect how healthy men respond to stress and fear.

More Fear trials

Quick facts

PhasePhase2; Phase3
Study typeInterventional
Ages18 Years to 50 Years
SexMen only
Enrollment60 (estimated)
SponsorUniversitaire Ziekenhuizen KU Leuven
Academic / other
Locations1 site (Leuven)
StatusRecruiting
StartedFebruary 2, 2023
Main results expectedJuly 2025
Study endsJuly 2025
Registry record updatedDecember 20, 2024
Trial IDNCT05587036 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are healthy male volunteers aged 18-50 with a BMI between 18.5-25 kg/m2.

Probably not a fit

Patients with a history of neurological, psychiatric, gastrointestinal, or endocrine disorders may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional trial investigates how rifaximin, an antibiotic, alters gut microbiota and its subsequent effects on stress sensitivity and fear-related processes in healthy men. Participants will be randomly assigned to receive either rifaximin or a placebo for two weeks, with a focus on understanding the psychobiological changes induced by the treatment. The study employs a triple-blind design to ensure unbiased results, and aims to identify factors that may mediate or moderate these changes.

Why it matters

Potential benefit: If successful, this study could provide insights into the relationship between gut health and emotional well-being, potentially leading to new treatments for stress and anxiety.

How similar studies have gone: While the relationship between gut microbiota and mental health is an emerging field, this specific approach using rifaximin is relatively novel and has not been extensively tested in similar studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
2. Proficiency in English and/or Dutch
3. Healthy with no intestinal and/or psychological complaints
4. Access to a -18°C freezer (i.e. ordinary household freezer)
5. Male participants
6. Age 18-50 years
7. BMI 18.5-25 kg/m2

Exclusion Criteria:

1. Participant has a history of previous or current neurological, psychiatric, gastrointestinal or endocrine disorder
2. Any disorder, which in the Investigator's opinion might jeopardize the participant's safety or compliance with the protocol
3. Any prior or concomitant treatment(s) that might jeopardize the participant's safety or that would compromise the integrity of the Trial
4. Participation in an interventional Trial with an investigational medicinal product (IMP) or device
5. Hypersensitivity to the active substance rifaximin, to any rifamycin (e.g. rifampicin or rifabutin) or any of the excipients
6. Current or recent medication use
7. Use of antibiotics within three months preceding the study
8. Current or recent (1-month) infection (e.g. common cold, influenza, COVID-19, etc.)
9. Previous or current substance/alcohol dependence or abuse (\>2 units per day or 14 units per week)
10. One or more diagnoses based on the mini international neuropsychiatric interview (MINI-S)
11. One or more diagnoses based on ROME IV for gastrointestinal disorders
12. Smoking
13. Night-shift work
14. Adherence to special diets (e.g. vegan, vegetarian, weight-loss, lactose-free, gluten-free, etc.)
15. Use of pre- or probiotics within one month preceding the study
16. Previous experience with any of the tasks used in the study (not including questionnaires)
17. Color vision deficiency (colorblindness)
18. Magnetic Resonance Imaging (MRI) contraindications, including claustrophobia, severe back problems, conditions that would interfere with MRI scanning (e.g. cochlear implant, metal fragments in eyes, metallic body inclusion, or other metal implanted in the body), and if the participant does not want to be informed of incidental findings that might be found during imaging.

Where it's running

  • UZ/KU Leuven
    Leuven, Belgium
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.